Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

REHOVOT, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in...
December 09, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product

Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023Based on current market sales...
December 02, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company,...
November 13, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019

Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.As a...
November 07, 2019 07:00 ET | Source: Kamada Ltd.

Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13

REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...
October 29, 2019 08:00 ET | Source: Kamada Ltd.

Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal

The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at the...
September 24, 2019 07:00 ET | Source: Kamada Ltd.

Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer,...
September 03, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and...
August 08, 2019 07:00 ET | Source: Kamada Ltd.

Kamada Reports Discussions with Takeda Regarding a Potential Extension of the Period for the Transition of GLASSIA Manufacturing to Takeda

REHOVOT, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda...
August 06, 2019 07:15 ET | Source: Kamada Ltd.

Kamada Reports Financial Results for Second Quarter and First Six Months of 2019

Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-YearTotal Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase Year-Over-YearGross Profit for...